Triazolam

Treats insomnia (generally 7 to 10 days). Sold as Halcion. Every FDA application for this active ingredient: 1 branded and 6 generic.

As of Nov 14, 2026, FDA lists 7 applications for Triazolam (sold as Halcion), first approved Nov 15, 1982, with 0 new uses approved and 0 published complete response letters.

First approved: Nov 15, 1982
Applications: 7
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $3.1M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name


Triazolam	Part D	$3.0M	-16%	49,999
Halcion	Part D	$35K	-15%	92

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

TRIAZOLAM 0.125 MG TABLET: $0.280 per unitGeneric · -29% in a year
TRIAZOLAM 0.25 MG TABLET: $0.332 per unitGeneric · -1% in a year

FDA Drug Safety Communications

One communication since 2020 that name this drug; see all communications

FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug classSep 23, 2020 · boxed warning

Clinical Trials

1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all

Study	Phase	Status	Posted
Measurement of the Hippocampal Theta Rhythm From the Outer Ear CanalAnxiety · University of Manitoba	Not applicable	Recruiting	May 17, 2019

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Nov 15, 1982	HalcionNDA 17892 · New molecular entity	Pfizer	39	Marketed
Mar 25, 1994	TriazolamANDA 74031	Pharmobedient	4	Discontinued
Jun 1, 1994	TriazolamANDA 74224	Hikma	10	Discontinued
Oct 20, 1995	TriazolamANDA 74445	Watson Labs	5	Discontinued
Oct 20, 2020	TriazolamANDA 214219	Ingenus Pharms LLC	4	Marketed
Nov 8, 2022	TriazolamANDA 216890	Breckenridge	1	Discontinued
Dec 28, 2022	TriazolamANDA 213003	Zydus Pharms	1	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA